Remove Arcturus Remove Blogging Remove Capital
article thumbnail

Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More

Xconomy

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84
article thumbnail

Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More

Xconomy

Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6

Funding 52